(NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results